Dual targeting of the antagonistic pathways mediated by Sirt1 and TXNIP











































Manipulation of metabolism and resistance to oxidative 
stress has been shown to promote longevity of small 
organisms [1, 2], and to some extent, these same 
mechanisms appear to act also in mammals despite 
considerable divergence during evolution[1]. One of the 
most described genes that inhibit oxidative stress and 
improve glucose metabolism is the histone deacetylase 
Sirt1 (for Silent information regulator T1). Evidence has  
been provided recently that Sirt1 negatively regulates 
oxidative stress [3-5] and protects cells against  damage  
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induced by H2O2, UV radiation, chemicals, and high 
caloric intake [6, 7]. In addition, this gene was found to 
regulate cellular metabolism through the stimulation of 
glucose uptake [8, 9] and insulin secretion [10-12], 
making it a promising target of putative anti-aging 
interventions [6, 10, 13].   
 
Little is known however about the contribution to the 
aging process of genes that act, in an opposite manner 
to Sirt1, to induce oxidative stress and disrupt glucose 
metabolism.  An example of such genes is the 
thioredoxin interacting protein (TXNIP) [14-16]. Early 
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cellular susceptibility to oxidative stress through direct 
interaction with the anti-stress enzyme, thioredoxin, and 
inhibition of its detoxifying functions [17). Over-
expression of this gene was postulated to cause the 
accumulation of reactive oxygen species and apoptotic 
cell death [18, 19]. More recently, evidence was 
provided that TXNIP may also act as a mediator of 
cellular metabolism. For instance, this gene was found 
to mediate glucose-induced apoptotic death in 
pancreatic beta cells, suggesting a causative relationship 
between TXNIP and type 2 diabetes [20, 21]. In support 
of this concept, TXNIP deficiency improved glucose 
uptake and attenuated diabetic symptoms in animal 
models [16, 22, 23]. Also, and as might be expected 
from these findings, an inverse correlation between 
TXNIP expression and longevity was recently reported 
[24-26] supporting the notion that this gene may act to 
negatively regulate the aging process.  
 
Taking into account this antagonistic relationship 
between Sirt1 and TXNIP regarding their effects on 
oxidative stress and metabolism (Figure 1), it is 
important to determine if, and how putative anti-aging 
approaches would affect the function of these two 





























between them. To address these possibilities, the 
present study investigated the effects of limited glucose 
availability (used here to mimic the effects of calorie 
restriction), the Sirt1 activator (resveratrol), and the 
hormone dehydroepiandrosterone (DHEA), on expres-
sion of Sirt1 and TXNIP in different cellular systems, 
including cancer, stem cells and a mice model. A 
potential link between these two genes and the 
underlying mechanisms leading to their regulation were 
also investigated. Our results indicated that each of the 
treatment approaches tested exerted effects on the 
expression of Sirt1 and TXNIP, however to various 
degrees. Interestingly limited glucose availability was 
the only approach that consistently reduced TXNIP 
expression in all the systems studied. Resveratrol and 
DHEA exerted inhibitory effects on TXNIP in a tissue 
specific manner, in addition, they were found to act on 
separate branches of the glycolytic pathway mediated 
respectively by AMPK and Glucose 6 phosphate de-
hydrogenase respectively. Overall, our findings suggest 
that dual targeting of antagonistic pathways implicated 
in the aging process must be considered in the design of 
anti-aging strategies. They also shed light on TXNIP as 
a downstream target of Sirt1 and therefore as a potential 
marker to predict or to evaluate the efficacy of putative 
































   



































Respective effects of limited glucose availability, 
resveratrol and DHEA on expression of Sirt1 and 
TXNIP in cancer cells 
 
The effects of limited glucose availability (used here to 
mimic the effect of calorie restriction), resveratrol (an 
activator of Sirt1) and DHEA (used for hormone 
replacement therapy), on the expression of TXNIP and 
Sirt1 were determined by Western blot using specific 
antibodies to the corresponding proteins (Figure 2).   
The data shows that cellular incubation with decreasing 
concentrations of glucose resulted in a dramatic loss of 
TXNIP expression (Figure 2A). Similar results were 
observed by using other cancer cell lines (Supplemental 
Data 1). Limited glucose availability was also found to 
cause a slight increase in the expression of Sirt1 (Figure 













































mediator of caloric restriction [27]. PCR analysis 
(Figure 2B) confirmed the previous findings and 
suggests that altered expression of TXNIP and Sirt1 in 
response to glucose deprivation occurred at the 
transcriptional level.   
 
Curiously, resveratrol had a biphasic effect on the 
expression of TXNIP, with a stimulatory action at low 
concentrations and inhibition at higher ones (Figure 2C 
and 2D). Even more intriguing is the finding that 
resveratrol suppressed the expression of its own target, 
Sirt1, in both RGC cells (Figure 2C) and SaOS2 cells 
(Figure 2D), at the same concentrations that inhibit 
TXNIP. These data suggest that regardless of the 
concentration used, resveratrol may exert unwanted 
effects. At low concentrations, it induces the expression 
of TXNIP, a potential antagonist with regards to Sirt1 
effect oxidative stress and metabolism, and at high 
concentrations, it inhibits expression of its own target. 
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administered should be carefully determined in order to 
achieving beneficial effects of this molecule.  
 
Dehydroepiandrosterone, DHEA is a hormone thought 
to play a role in aging based on the observation that its 
levels decline dramatically with age to reach values of 
30 to 20 % at 70 ~80 years [28]. Although some studies 
have suggested that replacement of this hormone at later 
age may have beneficial effects on illnesses such as 
atherosclerosis [29], autoimmune diseases [30], obesity 
[31], and  neurodegeneration [32], many studies failed 
to demonstrate any beneficial effect of this hormone on 
aging. At the molecular level, DHEA was shown to 
improve glucose uptake [33] and reduce the formation 
of reactive oxygen species [34], however, the putative 
roles of Sirt1 or TXNIP in mediating these actions are 
not known. Here we show that DHEA acts as a dual 
regulator of these two genes (Figure 2E). Exposure to 
increasing concentrations of this hormone resulted in 
decreased expression of both TXNIP and Sirt1. While 
the inhibition of TXNIP by this hormone is desirable, 
that of Sirt1 is not, suggesting that the anti-aging effects 
of DHEA, if any, would be hindered by its inhibitory 
effect on Sirt1 and related pathways. 
 
Overall, the findings presented in Figure 2 indicate that 
reduced calorie intake would rank the best among three  
approaches tested in this system. In contrast, 
suppression of Sirt1 by both resveratrol and DHEA may 
represent a major limitation to their potential use as 
anti-aging therapeutics. Nevertheless, a proper 
understanding of how these two treatments inhibit Sirt1 
will help in the development of approaches to avoid this 
“side effect” and improve their efficacy.  
  
Expression of Sirt1 and TXNIP in normal cells 
 
In order to obtain information on the physiological 
relevance of targeting Sirt1 and TXNIP in normal 
tissues, we investigated the effect of limited glucose 
availability, resveratrol and DHEA in differentiated 
aortic smooth muscle cells, and non-differentiated, 
human embryonic stem cells. As shown in Figure 3A, 
limited glucose availability inhibited TXNIP expression 
in smooth muscle cells, without any significant effect 
on Sirt1. Similar effects were also observed with 
resveratrol which inhibited the expression of TXNIP in 
a dose dependent manner. DHEA was without effect on 
any of the two genes (Figure 3A), raising the possibility 
that the glycolytic pathway targeted by this hormone 
may be altered in normal versus cancer cells. Of note, 
no significant changes in Sirt1 expression was observed 
in cells treated with any of the approaches tested, 
further confirming the difference in response to these 









































  Figure  3.  Effects  of  limited  glucose  availability,
resveratrol and DHEA on expression of TXNIP and Sirt1
in normal cells.  Aortic  smooth  muscle  cells  (panel  A)  and
human  embryonic  stem  cells  (panel  B)  were  treated  as
described  in  Figure  1  for  cancer  cells.  Expression  Sirt1  and
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account for this difference, we measured expression of 
Sirt1 and TXNIP in embryonic stem cells known for 
rapid self renewal ability. The human embryonic stem 
cells,BG01V, were subjected to glucose restriction or 
treatment with either resveratrol or DHEA under similar 
conditions to those described in Figure 2. As shown in 
Figure 3B, both Sirt1 and TXNIP were found to be 
expressed in human embryonic stem cells; however, none 
of these genes was affected by resveratrol or DHEA. In 
contrast, limited glucose availability strongly inhibited 
TXNIP with no significant effect on Sirt1 expression, 
mirroring its action on cancer (Figure 2) and smooth 
muscle cells (Figure 3A). Taken together, these findings 
suggest that the pathways targeted by resveratrol and 
DHEA may be altered in cancer versus normal cells, and 
that the effects of these two treatment may be tissue 
specific. In contrast, the consistent inhibition of TXNIP 
by limited glucose availability in cancer cells as well as 
in differentiated smooth muscle cells and non-differentia-
ted stem cells, is indicative of a potential role of this gene 


































Effect of resveratrol and DHEA on expression of 
Sirt1 and TXNIP in vivo 
 
In order to determine whether the observed effects in 
vitro could be also valid in vivo, we have subjected the 
nude mice (CD1 strain, Charles River) to treatment with 
either resveratrol or DHEA (10 mg/Kg each) for 2 days. 
The animals were then sacrificed and major organs 
harvested to analyze expression of Sirt1 and TXNIP by 
Western blot.  As shown in Figure 4, the relative 
expression of these two genes was tissue specific. While 
Sirt1 is expressed in most organs tested; TXNIP was 
found to be expressed mainly in the lung, kidney and 
the muscle. Both resveratrol and DHEA inhibited the 
expression of TXNIP in the lung, however only DHEA 
had an inhibitory effect in the muscle. Sirt1 was not 
significantly affect in most tissues except in the muscle 
of animals treated with DHEA. Taken together, these 
findings suggest that resveratrol and DHEA are capable 
of regulating the expression of TXNIP and Sirt1, 





































   





































Putative mechanisms by which DHEA and 
resveratrol regulate TXNIP and Sirt1 
  
The observation that TXNIP was consistently inhibited 
by all the treatments used in this study suggests that the 
signaling pathway leading to its expression may be a 
common target of these approaches. To define this 
pathway, we first investigated the implication of known 
targets of DHEA in mediating the effect of this 
hormone on TXNIP. Previous reports indicated that at 
the nuclear level, this hormone acts either through the 
peroxisome proliferator activated receptor alpha, 
pregnane X receptor, or the estrogen receptor [35]. At 
the plasma membrane, NMDA receptors and G-proteins 
were postulated to mediate the non-genomic action of 
DHEA [36, 37]. In the cytoplasm, DHEA was found to 














































phosphate dehydrogenase [38], a key glycolytic enzyme  
with a potential role in regulation of TXNIP.  However, 
a putative role of these pathways in the regulation of 
TXNIP and/or of Sirt1 has not been described.  
 
After subjecting SaOS2 cells to treatment with either an 
NMDA antagonist 3-[(+/-)-2-carboxypiperazin-4-yl] 
propyl-1-phosphonic acid (CPP), or an anti-estrogen 
drug (Tamoxifen), followed by cellular exposure to 
DHEA, the results (Figure 5A) indicate that neither 
CCP nor Tamoxifen reversed the inhibitory action of 
DHEA on TXNIP. Tamoxifen only partially reversed 
the effect of DHEA on Sirt1. Similar results were also 
obtained by using the RGC cells (Supplemental data 2), 
suggesting that these pathways may not play an 
important role in mediating the action of DHEA on 
TXNIP at least.  
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activation of the glucose 6 phosphate dehydrogenase 
  
Independently of the putative mechanisms described 
above, we have observed that cellular pre-treatment 
with DHEA almost completely blocked the effects of 
glucose on TXNIP expression (Figure 5B), suggesting 
that this hormone may act, at least in part, by interfering 
with the glycolityc pathways that regulate TXNIP 
expression. Since DHEA has also been shown to inhibit 
the glucose 6 phosphate dehydrogenase, G6PD [38], we 
investigated whether this possibility may account for 
the observed effects of this hormone on TXNIP. The 
results presented in Figure 5C show that the activity of 
G6PD was indeed strongly inhibited and in a dose 
dependent manner by DHEA. Of note, since this in vitro 
assay is based on the production of NADPH (half of 
which is produced by G6PD and the rest by other 
enzymes such as Malic acid dehydrogenase and 
isocitrate dehydrogenase [39], the data (Figure 5C) 
suggest that  the inhibitory effect of DHEA  on G6PD 
could be much higher than the 50% observed. 
Resveratrol has no effect on G6PD (Figure 5C) 
suggesting that it may act through a different pathway 






























Comparative effects of DHEA and resveratrol on 
AMP-activated protein kinase 
 
Recent investigations of the mechanisms by which 
resveratrol improves metabolism revealed that it 
induces phosphorylation of the AMP-mediated protein 
kinase (AMPK) [40], an enzyme that phosphorylates 
and inactivates the carbohydrate response element 
binding protein ChREB. However, the relevance of this 
action to the regulation of TXNIP by resveratrol and the 
possible implication of DHEA in regulating this 
pathway are not yet investigated. The results presented 
in Figure 6A show that resveratrol readily activates this 
enzyme (p-AMPK) in the retinal glial cells (RGC) 
without affecting expression of the corresponding gene 
(AMPK). Resveratrol also induced AMPK phospho-
rylation in the osteosarcoma cells SaOS2 (Figure 6B), 
however DHEA was without effect. These findings, in 
addition to those presented in Figure 5D, suggest that, 
although both molecules inhibit TXNIP, DHEA and 
resveratrol act through separate branches of the 
glycolytic pathway mediated by G6PD and AMPK 
respectively. Also, in light of the recent finding that 
Sirt1 is able to activate AMPK [41], our data suggest 
that TXNIP may be regulated by Sirt1 through this 
pathway (Figure 7). Further confirmation of this link 
will help establish TXNIP inhibition as an important 
determinant for evaluating the efficacy of putative anti-
aging interventions. The finding that limited glucose 
availability is the only approach that consistently 
inhibited expression of TXNIP in the all the systems 
used in this study, is in agreement with this concept and 
suggests that, regardless of Sirt1 levels, decreased 
expression of TXNIP may have beneficial effects for 




The main purpose of this study was to direct attention to 
the fact that antagonistic pathways implicated in the 
aging process must be simultaneously targeted for 
optimal anti-aging effects. As a proof of principle for 
this concept, we have chosen to analyze the regulation 
of Sirt1 and TXNIP in response to proven and unproven 
approaches thought to affect aging. Due to the 
antagonistic roles of these two genes in mediating the 
pathways that regulate oxidative stress and metabolism, 
we hypothesized that approaches that induce Sirt1 and 
inhibit TXNIP expression would be the most desirable. 
By comparing the effect of limited glucose availability, 
resveratrol and DHEA in this system (Figure 2), only 
limited glucose availability led to the expected results 
(induction of Sirt1 and inhibition of TXNIP), providing 
further support for the already established notion that 
calorie restriction is so far the only proven approach 
Figure  6.  Effect  of  Resveratrol  and  DHEA  on
phosphorylation  of  AMPK.  Panel  A,  SaOS2  cells  were
treated  with  increasing  concentrations  of  resveratrol  for  48
hours, after what, proteins were extracted and probed either
with anti‐phospho‐AMPK (Thr172), or with antibody to AMPK.
Panel  B,  RGC  cells  were  incubated  with  20  or  100  μM
resveratrol or DHEA 100 μM for 48 hours, and then probed for
phosphor‐AMPK and AMPK as described above.  
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found that depending on the dosage and the cell type 
used, resveratrol produced the unwanted effects of 
either inducing TXNIP or inhibiting the expression of 
its own target, Sirt1 (Figure 2C and 2D). Based on this, 
optimal beneficial effects of resveratrol against aging-
associated diseases would necessitate proper under-
standing of how this compound induces TXNIP at low 
doses and inhibits its own target at higher ones, a 
knowledge that will then be useful for the development 
of strategies to avoid these unwanted effects. In this 
regards, we have shown that AMPK is phosphorylated 
at Thr172 by resveratrol (Figure 6), and  in light of 
previous findings that AMPK is activated by 
phosphorylation at Thr172 and inhibited by phosphory-
lation at 485/491 [42], one could speculate that 
resveratrol may induce phosphorylation at 485/491 at 
low concentrations and at Thr172 at higher ones. This, 
and the mechanism(s) by which resveratrol inhibits the 
expression of its own target Sirt1, warrants further 



































this compound should  be administered without 
negatively influencing its own beneficial effects.  
 
Concerning the action of DHEA, the finding that this 
hormone inhibited, in a dose dependent manner, the 
expression of both Sirt1 and TXNIP puts it in an 
unfavorable position regarding its claimed beneficial 
effects against aging. Our findings rather provide an 
explanation for the controversy surrounding the use of 
DHEA in hormone replacement therapy for older 
population. However, since this hormone has at least one 
beneficial effect which is the inhibition of TXNIP, under-
standing the mechanism by which it inhibits Sirt1 may be 
helpful in the design of strategies to prevent this un-
wanted effect, and open new avenues for its use as an 
anti-aging therapeutic. In this regard, our results point to 
the possibility that the estrogen receptor could be a poten-
tial mediator of the undesirable effects of DHEA on Sirt1 
(Figure 5A), and suggest that a combination of DHEA 
with an estrogen receptor antagonist (i.e. Tamoxifen) 
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consistently similar in cancer and normal cells, those of 
resveratrol and DHEA were surprisingly different. In 
vitro experiments indicated that resveratrol but not 
DHEA affected TXNIP expression in aortic SMCs 
(Figure 3A), however, none of these two treatments 
altered the expression of this gene in embryonic stem 
cells (Figure 3B). In vivo the effects of resveratrol and 
DHEA were rather tissue specific (Figure 4) as they 
were limited mainly to the lung and muscle among all 
the organs tested. By comparison with the findings 
made in Figure 2 using cancer cells, the latter results 
suggest that the signaling pathways that regulate 
expression of Sirt1 and TXNIP may be altered in cancer 
versus normal tissues, particularly in stem cells where 
only limited glucose availability was able to affect the 
expression of TXNIP.   
 
The interesting finding that TXNIP was inhibited by all 
the treatments approaches tested in this study prompted 
us to investigate the underlying mechanism.  This led to 
the observation that both DHEA and resveratrol utilize 
the glycolytic pathway to inhibit TXNIP, however, they 
acted through two separate pathways mediated 
respectively by the inhibition of G6PDH (Figure 5) and 
the activation of AMPK (Figure 6). As shown in Figure 
7, expression of TXNIP appeared to be regulated, at 
least in part, by Sirt1 through activation of the AMPK, 
which in turn signals for the inhibition of nuclear 
translocation of ChREB and its association with Mlx1 
[43].  This, in light of the recent findings that Sirt1 
enhances the function of FOXO1α [44] and that the 
latter inhibits expression of TXNIP [26], is indicative of 
a negative regulatory relationship between Sirt1 and 
TXNIP through this pathway. Based on this, and due to 
its position far downstream of the glycolytic pathway 
regulated by Sirt1, TXNIP may represent putative target 
to mimic the effects of caloric restriction in a Sirt1-
dependend or even independent manner.   
 
In broader terms, our findings provided evidence for the 
concept that the development of strategies to delay the 
aging process must take into account the presence of 
antagonistic pathways such as those mediated by Sirt1 
and TXNIP on oxidative stress and metabolism. The 
observation that TXNIP acts as a downstream mediator 
of Sirt1 and a common target of various effectors of the 
glycolytic pathway, suggests that decreased expression 
of TXNIP alone may prove to be a reliable marker to 
evaluate and/or to predict the efficacy of putative anti-
aging therapies.  
 
 
MATERIALS AND METHODS 
 
The following drugs and reagents were obtained from the 
companies cited: DHEA; (+/-) CPP, Tamoxifen  (Sigma, 
St. Louis, MO); Antibody to acetylated p53  was 
obtained from upstate biotechnology (Lake placide NY); 
antibody to beta-actin from Sigma  (St. Louis, MO); 
secondary antibodies conjugated to horseradish 
peroxidase from BioRad (Hercules, CA); Enhanced 
chemiluminescence reagents (ECL) from Amersham 
(Arlington Heights, IL); Immobilon-P transfer membrane 
for Western blots from Millipore (Bedford, MA).  
 
Human monocytic cells (THP-1), osteosarcoma (SaOS2), 
breast carcinoma MCF-7 cells, the rat retinal ganglion 
cells (RGCs), aortic smooth muscle cells (SMCs) and the 
human embryonic stem cells BG01V1 were purchased 
from ATCC (Rockville MA). Dulbecco’s Modified 
Eagle’s Medium (DMEM), DMEM/F12 (1/1) medium, 
knockout serum and fetal bovine serum (FBS) were 
obtained from Invitrogen (Carlsbad, CA).  Cancer cell 
lines, HUVEC and SMC cells were maintained in their 
corresponding culture media and subjected to treatment 
with resveratrol or DHEA at concentrations ranging from 
0 to 80 μM, or incubated in culture media with decreased 
glucose concentrations. After 48 hours of incubation, the 
cells were washed with PBS and re-suspended in 100 μl 
of lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 
100 mM NaF, 1 mM MgCl2, 1.5 mM EGTA, 10% 
glycerol, 1% Triton X100, 1 μg/ml leupeptin, 1 mM 
phenyl-methyl-sulfonyl-fluoride). Equal amounts of 
proteins were analyzed by Western blot for expression of 
Sirt1 and TXNIP.  
 
The human embryonic stem cells were cultivated in 
DMEM/F12 (1:1) supplemented with 40% knockout 
serum, 10 mM L-glutamine, and 1 mM non essential 
amino acids, and 10 µg/ml bFGF, and grown on mouse 
embryonic fibroblasts (MEFs) as feeders. Treatments 
with resveratrol, DHEA, or reduced glucose content 
were carried out as described above. After 48 hours of 
incubation, the cells were washed with PBS, treated 
with collagenase for 5 min at 37ºC. The detached 
colonies were pelleted by centrifugation at 500xg for 5 
min to separate them from floating MEFS. The pellets 
were re-suspended in lysis buffer as described above 
and proteins processed by Western blot, as described 
previously [45], to measure the expression of Sirt1 and 
TXNIP. Briefly, equal quantities of protein were 
separated by electrophoresis on a 12% SDS-PAGE gel 
and transferred to Immobilon-P membranes.  Proteins of  
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primary and secondary antibodies linked to horseradish 
peroxidase and detected by chemiluminescence [45]. 
 
PCR reaction.  Total
  RNA was isolated using Qiagen 
Rneasy mini kit (Qiagen
  Inc., Valencia, CA) as 
recommended by the supplier. Total RNA
  was 
quantified by OD at 260 nm. Using equal amount of 
total RNA (200
  ng), stimulated under various 
conditions, mRNA was
 primed with random hexamers, 
and complementary DNA (cDNA) was
  synthesized 
from mRNA by TaqMan reverse transcription with
 
MultiScribe reverse transcriptase (PE Applied 
Biosystems, Foster,
 CT) according to the manufacturer's 
description. The final
  cDNA product was used for 
subsequent cDNA amplification by
  polymerase chain 
reaction.
 cDNA was amplified and quantitated by using 
SYBR Green PCR reagents
  from PE Applied 
Biosystems according to the manufacturer's
 instructions. 
The cDNA for GAPDH was amplified by using a 
specific forward
 primer (5'-GAA GGT GAA GGT CGG 
AGT C-3') and a specific reverse primer
 (5'-GAA GAT 
GGT GAT GGG ATT TC-3'). The primers for TXNIP 
were: CTG GCG TAA GCT TTT CAA GG (forward) 
AGT GCA CAA AGG GGA AAC AC (reverse). The 
primers for Sirt1 were: 5’-ATA GCA CAC AAA CAT 
CAT GCA-3’ (forward) and 5’-TTT ATG CAT AAA 
ACA CCC AGC-3’ (reverse). The PCR
  reaction 
mixture (final volume 25 µl) contained 5 µl
 of cDNA, 1 
µl of 10 µM forward primer, 1 µl
 of 10 µM reverse 
primer, 2.5 µl of PCR 10x SYBR
 Green PCR buffer, 3 
µl of 25mM MgCl2, 2 µl of dNTP
 mix (2.5 mM dATP, 
2.5 mM dCTP, 2.5 mM dGTP, and 5 mM dUTP),
 0.125 
µl of AmpliTag Gold DNA polymerase (5 units/µl
 
AmpliTag Gold DNA polymerase), and 10.125 µl of 
H2O.
  The reaction was amplified with iCycler iQ 
Multicolor
 Real Time PCR Detector (Bio-Rad) for 37 
cycles with melting
 at 94 °C for 30 s, an annealing at 58 





Glucose 6 phosphate dehydrogenase activity. Enzyme 
activity assays were performed using the Vybrant. 
Assay Kit (V-23111, Molecular Probes, Eugene, OR) 
with minor changes to allow monitoring of cytosolic 
enzyme glucose 6-phosphate dehydrogenase in protein 
extracts. Briefly cells from a 75 cm
2 flask were lysed in 
(50 mM HEPES pH 7.4, 150 mM NaCl, 100 mM NaF, 
1 mM MgCl2, 1.5 mM EGTA, 10% glycerol, 1% Triton 
X100, 1 μg/ml leupeptin, 1 mM phenyl-methyl-
sulfonyl-fluoride) and diluted to a final concentration of 
0.5 mg/mg in PBS.  Samples containing 50 μl of this 
solution were added to a 96 well plate and incubated in 
the absence or the presence of DHEA or resveratrol for 
10 min at room temperature. The 2X reaction mixture 
containing the G6PD substrate resazurin was prepared 
as recommended by the manufacturer.  The reaction 
was then started by addition of 50 μl of the reaction 
mixture to the protein samples, followed by incubation 
for 10 min at room temperature. The plate is then placed 
in a fluorescence microplate reader set up at the 
excitation 530 and emission 580 nm and fluorescence 
values recorded.   
 
In vivo experiments. Mice were injected with DHEA or 
resveratrol (10 mg/Kg each) and after 48 hours, the 
animals were sacrificed and tissues harvested. To 
measure the levels of TXNIP and Sirt1, tissues were 
homogenized on ice in 300 μl of lysis buffer per gram 
of tissue. The lysates were then centrifuged at 1, 000xg 
for 5 min at 4ºC and proteins in the supernatant 
quantified and processed for Western blot as described 
above.   
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